Pulsed Dye Laser (PDL) vs. Microsecond 1064-nm Nd:YAG Laser for Treatment of Diffuse Facial Redness

Not Applicable

Completed

• Conditions: Rosacea
• Interventions: Procedure: Pulse Dye Laser/YAG laser

• Registration Number: NCT01529996
• Lead Sponsor: Northwestern University

Brief Summary

The primary objective of this study is to compare the efficacy of PDL and the 1064-nm Nd:YAG laser in the treatment of facial redness.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2012-01
• Study First Submitted: 2012-02-07
• Study First Submitted QC: 2012-02-08
• Study First Posted: 2012-02-09
• Primary Completion: 2012-08
• Study Completion: 2012-08
• Status Verified: 2021-11
• Last Update Submitted: 2021-11-30
• Last Update Posted: 2021-12-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

• Healthy patients 18-55 years of age with erythematotelangiectatic rosacea (as verified by the the PI).
• Subjects who are willing to provide informed consent for participation in the study.

Read More

Exclusion Criteria

• Pregnant or lactating individuals
• Subjects who are unable to understand the protocol or to give informed consent.
• Subjects who have a known history of photosensitive conditions (e.g. Systemic lupus, polymorphous light eruption)
• Subjects who have facial telangiectasia of diameter greater than 2 mm.
• Subject who have significant (as determined by the PI) acute inflammatory papules, pustules, and vesicle involving the central face.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
YAG laser	Pulse Dye Laser/YAG laser	-
Pulse Dye Laer	Pulse Dye Laser/YAG laser	-

Primary Outcome Measures

Name	Time	Method
Rating on global improvement scale	four months	Non-treating dermatologists will rate each side of the face using a global improvement scale to evaluate the effectiveness of the two treatments.
Spectrophotometer measurement	four months	Spectrophotometer measurement as the percent resolution on each follow up visit compared to baseline visit

Secondary Outcome Measures

Name	Time	Method
Recorded discomfort	four months	Subjects will record discomfort using a 10-point scale
Patient satisfaction	four months	Patients will record satisfaction on the questionnaires provided
Adverse events	four months	Any adverse events will be recorded

Trial Locations

Locations (1)

Northwestern University Feinberg School of Medicine, Department of Dermatology; 🇺🇸 Chicago, Illinois, United States